Founded Year
2007Stage
PIPE | IPOTotal Raised
$95.34MMarket Cap
0.47BStock Price
2.67About Akebia Therapeutics
Akebia Therapeutics is focused on discovering and developing therapeutic solutions leveraging the potential of the hypoxia-inducible factor - or HIF - biology. HIF-Prolyl Hydroxylase inhibition could represent an approach to treating certain conditions where there is an unmet need.
Akebia Therapeutics Headquarter Location
245 First Street Suite 1400
Cambridge, Massachusetts, 02142,
United States
617-871-2098
Latest Akebia Therapeutics News
Nov 24, 2021
News provided by Share this article Share this article CAMBRIDGE, Mass., Nov. 24, 2021 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA ), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, and David A. Spellman, Chief Financial Officer, will participate in the following investor conferences: Piper Sandler 33rd Annual Virtual Healthcare Conference November 29 – December 2, 2021 John Butler will participate in a virtual fireside chat, which will be available on the conference site prior to the virtual event. 4th Annual Evercore ISI HealthCONx Conference November 30 - December 2, 2021 John Butler will participate in a virtual fireside chat, which will be presented on Tuesday, November 30 at 4:45 on the conference site. Where applicable, webcasts of Akebia's fireside chats will be made available on the Investors section of the Company's website at https://ir.akebia.com . About Akebia Therapeutics Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com , which does not form a part of this release. Akebia Therapeutics Contact
Expert Collections containing Akebia Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Akebia Therapeutics is included in 1 Expert Collection, including Biopharmaceuticals.
Biopharmaceuticals
14,140 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Akebia Therapeutics Patents
Akebia Therapeutics has filed 30 patents.
The 3 most popular patent topics include:
- Transcription factors
- Acetic acids
- Pyridines
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
2/10/2020 | 7/20/2021 | Hepatotoxins, Acetic acids, Metal halides, Pyridines, Carboxamides | Grant | |
Application Date | 2/10/2020 | ||||
|---|---|---|---|---|---|
Grant Date | 7/20/2021 | ||||
Title | |||||
Related Topics | Hepatotoxins, Acetic acids, Metal halides, Pyridines, Carboxamides | ||||
Status | Grant |
